Carisma Therapeutics unveiled data and preliminary findings from a phase I clinical trial of CT-0508 catering to individuals afflicted with HER2-positive solid tumours, as highlighted at the American Society for Gene and Cell Therapy conference in 2023, with a particular emphasis on its safety, tolerability, efficacy in cell production, transportation, and modulation of the tumour microenvironment [48]. Here, ERBB2 is linked to neoplasm.